• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

Allergan's a Bargain That Could Pop 20%

When it comes to Perrigo, many stubborn traders have been transformed into long-term investors.
By TIMOTHY COLLINS
Dec 21, 2016 | 11:39 AM EST
Stocks quotes in this article: PRGO, AGN

It's getting cold outside and traders are slowly freezing. At least that's the way it feels when you examine the volume and volatility here. After such a strong run since the election, I imagine a few folks are taking an early holiday. A few may even be taking some profits here, so they can head to the store and buy their kid the G.I. Joe with a kung fu grip. I'm continuing to stockpile my list for after the holidays rather than attack the trading floor. I think it the most prudent activity at the moment.

Perrigo (PRGO) has 2016 in the book as a year to forget. The problem is I don't know if 2017 is going to start off as much of a year to remember. The stock has put in two half-hearted attempts to rally since the huge gap down in the spring. For the buyers left over from 2015, they are praying for a buyout simply to cut losses, but the chances of seeing green are a lottery ticket at this point. Nothing is impossible, but many stubborn traders have been transformed into long-term investors. Every one of those folks is waiting to sell when the stock gets to a price where the loss is "tolerable."

PRGO is stuck in a descending triangle pattern, and a weekly close under $82.50 should trigger another painful leg lower. While we've watched the MACD turn high it hasn't meant much. The large gap lower has given the illusion of some underlying technical strength, but until we see prices trade above the 13-week simple moving average as well as that pattern of lower highs, there is no hurry to scoop up Perrigo.

If I really wanted to bargain hunt in this area, then my attentions would turn to Allergan (AGN) . The stock hasn't shown much either in 2016, but we are seeing a bit of life here with a hammer pattern forming this week. The concern is the basing over the past six weeks is a bear flag. The simple approach is to close any long position should the stock close under $190. For buyers here, that's not a big risk vs. the near-term upside range of $208 to $215. We seem to be setting up for multiple bullish crossovers to match the one currently in place with the StochRSI. The past crossovers, even though they've reversed, have been good for 10% to 20% moves before fading again. That would put a return to $220, possibly even $240, on the plate for 2017. I'd be quite happy taking profits there. This is one of the few I'll dip my toes into in 2016.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Collins was long AGN, although positions may change at any time.

TAGS: Investing | U.S. Equity | Healthcare | Stocks

More from Healthcare

Johnson & Johnson Appears to Be Running Out of Steam

Bruce Kamich
Jun 22, 2022 8:25 AM EDT

The shares of the healthcare giant have been in a long-term uptrend but could break that trend in the weeks ahead.

Anthem's Long-Term Uptrend Is Losing Its Vigor

Bruce Kamich
Jun 22, 2022 7:40 AM EDT

The technical signals of the health benefits provider are weakening.

Here Are 2 Prudent Healthcare Trades

Bret Jensen
Jun 17, 2022 11:30 AM EDT

The country might be heading into recession, but folks still need to get their medicine, good times or bad.

Here's the Level to Zero In on for UnitedHealth Group

Bruce Kamich
Jun 13, 2022 7:29 AM EDT

Shares of the diversified healthcare company have held up fairly well despite the decline in the broader market but soon could be put to the test.

3 Dividend-Paying Healthcare Stocks That Age Well

Bob Ciura
Jun 5, 2022 12:30 PM EDT

Within the next 15 years, people 65 or older are expected outnumber those under 18, for the first time in U.S. history.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 08:55 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    The 10 personality traits of successful traders an...
  • 12:08 PM EDT STEPHEN GUILFOYLE

    Stocks Under $10

    As a Portfolio Name Agrees to a Merger, Here's Our...
  • 10:44 AM EDT PAUL PRICE

    My Very Best Pick for the Next 12 Months

    American Woodmark . It rarely gets better than th...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login